title: The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.
abstract: Overexpression of the oncogene amplified in breast cancer 1 (AIB1)/steroid receptor coactivator-3 (SRC-3) induces mammary tumorigenesis in mice. In breast cancer, high levels of AIB1/SRC-3 and the growth factor receptor HER2/neu predict resistance to endocrine therapy and poor outcome. However, a mechanistic relationship between AIB1/SRC-3 and HER2/neu in the development of breast cancer has not been shown. Here, we show that deletion of one allele of SRC-3 significantly delays Neu-induced mammary tumor development in mice. Homozygous deletion of SRC-3 in mice completely prevents Neu-induced tumor formation. By ages 3 to 4 months, Neu/SRC-3(+/-) mice exhibit a noticeable reduction in lateral side-bud formation, accompanied by reduced cellular levels of phosphorylated Neu compared with Neu/SRC-3(wt) mice. In Neu-induced tumors, high levels of SRC-3, phosphorylated Neu, cyclin D1, cyclin E, and proliferating cell nuclear antigen expression are observed, accompanied by activation of the AKT and c-Jun NH(2) kinase (JNK) signaling pathways. In comparison, phosphorylated Neu, cyclin D1, and cyclin E are significantly decreased in Neu/SRC-3(+/-) tumors, proliferation is reduced, and AKT and JNK activation is barely detectable. Our data indicate that AIB1/SRC-3 is required for HER2/neu oncogenic activity and for the phosphorylation and activation of the HER2/neu receptor. We predict that reducing AIB1/SRC-3 levels or activity in the mammary epithelium could potentiate therapies aimed at inhibiting HER2/neu signaling in breast cancer.
authors.affiliation: Departments of Oncology and Pharmacology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA.
authors.forename: Mark P
authors.initials: MP
authors.lastname: Fereshteh
authors.forename: Maddalena T
authors.initials: MT
authors.lastname: Tilli
authors.forename: Sung Eun
authors.initials: SE
authors.lastname: Kim
authors.forename: Jianming
authors.initials: J
authors.lastname: Xu
authors.forename: Bert W
authors.initials: BW
authors.lastname: O'Malley
authors.forename: Anton
authors.initials: A
authors.lastname: Wellstein
authors.forename: Priscilla A
authors.initials: PA
authors.lastname: Furth
authors.forename: Anna T
authors.initials: AT
authors.lastname: Riegel
mesh_terms: D000483:Alleles; D000818:Animals; D049109:Cell Proliferation; D004848:Epithelium / Q000378:metabolism; D017353:Gene Deletion; D051548:Histone Acetyltransferases / Q000235:genetics* / Q000378:metabolism / Q000502:physiology*; D048670:MAP Kinase Kinase 4 / Q000378:metabolism; D015674:Mammary Neoplasms, Animal / Q000235:genetics* / Q000378:metabolism*; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D056921:Nuclear Receptor Coactivator 3; D010766:Phosphorylation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D015398:Signal Transduction; D015534:Trans-Activators / Q000235:genetics* / Q000378:metabolism / Q000502:physiology*
chemical_list: D051548:Histone Acetyltransferases; D048670:MAP Kinase Kinase 4; D056921:Nuclear Receptor Coactivator 3; D018719:Erb-b2 Receptor Tyrosine Kinases; D015534:Trans-Activators; C538867:Ncoa3 protein, mouse